Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company’s most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. “We are delighted with the final data,” Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration “to determine next steps” for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a “breakthrough” drug by the FDA last April based on initial data from the trial. The FDA grants “breakthrough” status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.

Output: Pfizer Inc’s experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study’s primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.


Input: Consider Input: Paragraph: Washington state’s largest metropolis sweated through its hottest June on record, going fortnights without even a drizzle. Seattleites jokingly refer to the month of “Juneuary” for the wet and cold they usually endure before longer, dryer sunny days arrive in July, typically persisting into September. This summer, however, they have shrugged off the rain gear and flannel and taken to drinking “iced” lattes. Many, including Mayor Ed Murray, find themselves oddly yearning for the cloud cover on which Rain City’s identity was forged. Murray said the heat has kept him up at night in his brick Tudor-style house, which he has nicknamed the “little Dutch oven.”  “Obviously people in Seattle love a little more sun but also nothing is built for it,” Murray said. “I miss my rain.”  With an estimated 662,400 residents, the Emerald City, as the city is nicknamed, lies between the brackish Puget Sound and the Cascade Mountains which squeeze moisture out of east-bound fronts moving over the city. It is so dry in the state that a wildfire is burning in a  rainforest on the Olympic Peninsula and Governor Jay Inslee issued a statewide drought emergency in May as the snowpack in the mountains fell to historic lows. Seattle-Tacoma International Airport received just 0.23 inches (0.58 cm) of rain for June, down from the normal 1.57 inches (3.98 cm). To be sure, drought conditions are affecting cities down the U.S. West Coast, which is embroiled in a particularly fierce wildfire season that has prompted water-use and burn restrictions. Seattle’s public utility downgraded the water supply outlook from “good” to “fair” on Wednesday amid higher-than-usual water consumption and record-low stream flows into reservoirs, urging residents to limit plant-watering. Murray said the city had enough water and energy this year but was being pushed to the limit. “A second year with such little snowpack would be a crisis,” he said, referring to the affect on the broader region’s cold, clear salmon rivers and bountiful farms and orchards. While the current situation is “mega extreme in terms of our temperatures,” it is unlikely that it is caused by human-induced global warming because the heat-wave is due to an unusual large-scale air pattern, University of Washington atmospheric sciences professor Clifford Mass said. Relief is forecast heading into the weekend, with a chance of rain on Sunday and cooler temperatures in the week ahead, Mass said. But overall the summer will be warmer than normal as Seattle enters it driest period of the year. Meanwhile, parched lawns have turned beige and the city opened cooling shelters. At local hardware stores, air conditioning units and fans have been flying off the shelves; one Lowes store sold 16 air-conditioning units in a matter of minutes after it opened. “This is Sicily in Seattle, with nearly 16 hours of daylight,” Seattle-born author Timothy Egan wrote in the New York Times on July 3. Some people have embraced the dry skies and sun. “Everybody is a bit nicer. People say ‘Hi’ to each other. It’s not the hanging their head when they walk by each other,” said Nicole Sullivan, a management consultant who has used the heat as an opportunity to take her paddle board on Shilshole Bay on balmy evenings. “How do we re-market ourselves if we are not ‘Rain City’ or the ‘Emerald City,’?” Mayor Murray deadpanned. “If we’re not green anymore, what’s going to be our new color?” Claim: Residents in soggy Seattle rebel against the sun.

Output: Seattle’s mayor is losing sleep over the unusually hot, dry weather that is causing a run on air conditioners and fans in the famously rainy city.


Input: Consider Input: Paragraph: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer’s complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche’s Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. “It’s one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease,” said Daniel O’Day, the head of Roche’s Pharmaceuticals division. Loxo’s larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo’s study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co’s Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical’s O’Day welcomed a wider field. “Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we’re entering,” he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen’s Rigshospitalet, who co-authored the larotrectinib study. “You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them.”  Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis. Claim: Roche takes on Loxo, Bayer in gene-defined cancer class.


Output: Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area.